Publicaciones en colaboración con investigadores/as de University of Virginia (34)

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome

    Journal of Allergy and Clinical Immunology, Vol. 151, Núm. 4, pp. 1081-1095

2021

  1. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

    Journal of Clinical Oncology, Vol. 39, Núm. 33, pp. 3725-3736

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

    Human Genetics and Genomics Advances, Vol. 2, Núm. 3

  4. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

    European Journal of Cancer, Vol. 148, pp. 411-421

2020

  1. Effect of pharmacological inhibition of the catalytic activity of phosphatases of regenerating liver in early t cell receptor signaling dynamics and IL-2 production

    International Journal of Molecular Sciences, Vol. 21, Núm. 7

2019

  1. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)

    Nature Communications

  2. Shared heritability and functional enrichment across six solid cancers

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

    The Lancet Neurology, Vol. 17, Núm. 5, pp. 405-415

2016

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920

  2. Effect of diastolic dysfunction on postoperative outcomes after cardiovascular surgery: A systematic review and meta-analysis

    Journal of Thoracic and Cardiovascular Surgery, Vol. 152, Núm. 4, pp. 1142-1153

  3. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Adjuvant chemoradiation in pancreatic cancer: A pooled analysis in elderly (≥75 years) patients

    Anticancer Research, Vol. 35, Núm. 6, pp. 3441-3446

  2. Essential versus accessory aspects of cell death: Recommendations of the NCCD 2015

    Cell Death and Differentiation, Vol. 22, Núm. 1, pp. 58-73

  3. Tres problemas y tres soluciones para la Universidad española del siglo XXI

    CIAN. Revista de historia de las universidades, Vol. 18, Núm. 1, pp. 55-78

2014

  1. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 90, Núm. 4, pp. 911-917

2010

  1. Identifying predictors of central nervous system disease in solid organ transplant recipientswith cryptococcosis

    Transplantation, Vol. 89, Núm. 1, pp. 69-74

  2. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients

    Clinical Infectious Diseases, Vol. 51, Núm. 9, pp. 1062-1069